PolyCore Pipeline

PolyCore is currently conducting preclinical studies of its novel small molecule lead compound, PCT-3012, for treatment of Parkinson’s motor symptoms and dyskinesia in patients with early- to mid-stage Parkinson’s Disease (PD).

Results from preclinical studies in animal models demonstrate improved motor performance, alone and in combination with L-dopa, does not cause dyskinesia, and reduces involuntary movements associated with L-dopa administration.  Studies have also shown improvement in cognition and sustained attention.

We are exploring indications of PCT-3012 for the treatment of ADHD, Huntington’s disease and other dyskinesia and cognitive disorders, applying its differentiated mechanism of action to deliver new potential treatments.

 

The Science Behind PCT-3012

To learn more about this novel compound’s highly differentiated
mechanism of action, click here.